Full-Time

RN Ambulatory

Allergy and Immunology

Confirmed live in the last 24 hours

Cleveland Clinic

Cleveland Clinic

Non-profit academic medical center providing healthcare

No salary listed

Junior, Mid

Company Does Not Provide H1B Sponsorship

Mayfield Heights, OH, USA

The job is located at Hillcrest Hospital in Mayfield Heights, Ohio.

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Requirements
  • Graduate from an accredited School of Nursing
  • Current state licensure as a Registered Nurse (RN)
  • Basic Life Support (BLS) Certification through the American Heart Association (AHA)
  • One year of recent experience as an RN OR LPN, Medical Assistant and/or other unlicensed clinical healthcare experience if applicant is a current Cleveland Clinic caregiver in an ambulatory setting transferring into an RN role but remaining in the same current ambulatory Cleveland Clinic setting OR a current Cleveland Clinic caregiver in a clinical role within the same specialty area transferring into an ambulatory area
Responsibilities
  • Provide professional nursing care in an ambulatory setting.
  • Assess health status, complete nursing assessments, perform telephone triage and establish care plans.
  • Administer medications and treatments.
  • Initiate CPR and other emergency measures.
  • Notify the physician and/or Licensed Independent Provider (LIP) of abnormal findings.
  • Assist with specialized diagnostic procedures, therapeutic procedures and specialized patient care equipment.
  • Develop, evaluate, adapt and document health education and provide it to patients and families.
  • Cover other nursing roles within the department.
  • Travel within the region to support physician clinics and surgical procedures, as needed.
Desired Qualifications
  • Bachelor’s of Science in Nursing (BSN)

Cleveland Clinic is a non-profit academic medical center that provides high-quality clinical and hospital care, serving patients, families, and healthcare professionals. It offers a range of services including routine check-ups, specialized treatments, and virtual visits, with multiple locations across Ohio, Florida, Abu Dhabi, and Canada. The clinic stands out from competitors through its commitment to safety, quality care, and its focus on medical research and education. Its goal is to deliver exceptional medical care while advancing healthcare knowledge and training future professionals.

Company Size

N/A

Company Stage

Grant

Total Funding

$74.7M

Headquarters

Cleveland, Ohio

Founded

1921

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased investment in AI healthcare solutions enhances Cleveland Clinic's data analysis capabilities.
  • Neuromodulation therapies present opportunities for treating conditions like obstructive sleep apnea.
  • Collaboration on virtual neighborhoods using EHR data offers community health insights.

What critics are saying

  • Competition from AI healthcare companies may challenge Cleveland Clinic's data management.
  • Neuromodulation therapies could shift patient preferences from traditional treatments.
  • Developing virtual neighborhoods with EHR data may pose data privacy challenges.

What makes Cleveland Clinic unique

  • Cleveland Clinic offers comprehensive medical services, including virtual visits and second opinions.
  • It operates globally with facilities in Ohio, Florida, Abu Dhabi, and Canada.
  • The clinic supports healthcare providers with resources like DrConnect and eRadiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Mental Health Support

Company News

Finsmes
Dec 12th, 2024
1m Raises $10M in Series A Funding

1m raises $10M in Series A funding.

Hit Consultant
Oct 24th, 2024
Dyania Health Secures $10M for AI-Powered Chart Review

Dyania Health, an AI-powered healthcare data company, today announced the close of its $10 million Series A funding round led by Health..

PR Newswire
Aug 21st, 2024
Xii Medical Raises $45 Million In Series B Financing To Advance Best-In-Class Neuromodulation Therapy For Obstructive Sleep Apnea

Omega Funds and Intuitive Ventures join top-tier syndicate of healthcare investors to support ongoing clinical activitiesUNION CITY, Calif., Aug. 21, 2024 /PRNewswire/ -- XII Medical, Inc., a clinical-stage medical technology company developing innovative therapies for obstructive sleep apnea, today announced the closing of a $45 million Series B equity financing. The financing was led by Omega Funds and joined by new investor Intuitive Ventures. Existing investors also participated, including founding investor Cleveland Clinic, Ajax Health, Longview Ventures (an affiliate of Broadview Ventures), Aperture Venture Partners, JobsOhio Growth Capital Fund and an undisclosed strategic investor. Funds will be utilized to further product and clinical development. XII Medical has developed a state-of-the-art, patient-centric neuromodulation therapy designed to enhance quality of life for the millions of people suffering from obstructive sleep apnea.Obstructive sleep apnea (OSA) is a disorder in which the muscles in the throat temporarily relax, causing blockage of the airway during sleep

Finsmes
Aug 6th, 2024
Neurotherapia Raises $12.3M In Series B Funding

NeuroTherapia, a Cleveland, OH-based clinical-stage company focused on developing therapies for neurodegenerative diseases, raised $12.3M in Series B funding.The round was led by Cleveland Clinic, and included all previous investors, Brain Trust Accelerator Fund II, Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF) as well as new investors, Foundation for a Better World and CRUINT. Led by President and CEO Tony Giordano, NeuroTherapia is a clinical-stage biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other CNS conditions. NeuroTherapia is developing therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid.The company intends to use the funds for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer’s disease (AD). NeuroTherapia will continue to raise additional funds for its second close in six months, which will enable development of a recently discovered second generation molecule for a separate indication in which neuroinflammation plays a major role.FinSMEs06/08/2024

PR Newswire
Aug 1st, 2023
Enspire DBS Therapy Announces $17.6 Million Series B Financing to Advance the Development of Deep Brain Stimulation (DBS) plus Rehabilitation for Stroke Patients

/PRNewswire/ -- Enspire DBS Therapy, Inc., (Enspire) a clinical stage company developing an implantable neuromodulation therapy for post-stroke recovery,...